View source for 4rlk


==Crystal structure of Z. mays CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate==
<StructureSection load='4rlk' size='340' side='right'caption='[[4rlk]], [[Resolution|resolution]] 1.24&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[4rlk]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Zea_mays Zea mays]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4RLK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4RLK FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.24&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=E91:4-[(E)-(9H-FLUOREN-9-YLIDENEHYDRAZINYLIDENE)METHYL]BENZOIC+ACID'>E91</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4rlk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4rlk OCA], [https://pdbe.org/4rlk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4rlk RCSB], [https://www.ebi.ac.uk/pdbsum/4rlk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4rlk ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CSK2A_MAIZE CSK2A_MAIZE] Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. The alpha chain contains the catalytic site.
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Screening for protein kinase CK2 inhibitors of the structural diversity compound library (DTP NCI/NIH) led to the discovery of 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl]benzoic acid (E9). E9 induces apoptotic cell death in various cancer cell lines and upon hypoxia, the compound suppresses CK2-catalyzed HSP90/Cdc37 phosphorylation and induces HIF-1alpha degradation. Furthermore, E9 exerts a strong anti-tumour activity by inducing necrosis in murine xenograft models underlining its potential to be used for cancer treatment in future clinical studies. Crystal structure analysis of human and maize CK2alpha in complex with E9 reveals unique binding properties of the inhibitor to the enzyme, accounting for its affinity and selectivity.

Protein kinase CK2 inhibition is associated with the destabilization of HIF-1alpha in human cancer cells.,Guerra B, Rasmussen TD, Schnitzler A, Jensen HH, Boldyreff BS, Miyata Y, Marcussen N, Niefind K, Issinger OG Cancer Lett. 2015 Jan 28;356(2 Pt B):751-61. doi: 10.1016/j.canlet.2014.10.026., Epub 2014 Oct 28. PMID:25449433<ref>PMID:25449433</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 4rlk" style="background-color:#fffaf0;"></div>

==See Also==
*[[Casein kinase 3D structures|Casein kinase 3D structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Zea mays]]
[[Category: Boldyreff BS]]
[[Category: Guerra B]]
[[Category: Issinger OG]]
[[Category: Jensen HH]]
[[Category: Marcussen N]]
[[Category: Miyata Y]]
[[Category: Niefind K]]
[[Category: Rasmussen TDL]]
[[Category: Schnitzler A]]